Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
National Institutes of Health · Department of Health and Human Services · RFA-DA-26-034
In plain English
National Institutes of Health (Department of Health and Human Services) is accepting applications for this grant until Nov 18, 2027 (372 days left).
Awards are up to $300,000 each and estimated total program funding is $300,000.
Eligible applicant types include nonprofits, small businesses, for-profit companies, state governments, local governments, tribal governments & organizations, colleges & universities, school districts and public housing authorities, plus others described in the listing.
The listing says cost sharing or matching is not required.
Built only from the fields in the Grants.gov listing. Always confirm on the official listing.
Key facts
| Status | Posted: open for applications |
|---|---|
| Close date | Nov 18, 2027 · 372 days left |
| Posted date | Nov 20, 2024 |
| Opportunity number | RFA-DA-26-034 |
| Agency | National Institutes of Health (Department of Health and Human Services) |
| Funding instrument | Grant |
| Category | Education, Health |
| Opportunity category | Discretionary |
| Award ceiling (max per award) | $300,000 |
| Award floor (min per award) | Not stated |
| Estimated total program funding | $300,000 |
| Expected number of awards | Not stated |
| Cost sharing or matching required | No |
| Assistance listing (CFDA/ALN) | 93.233 – National Center on Sleep Disorders Research 93.279 – Drug Use and Addiction Research Programs 93.837 – Cardiovascular Diseases Research 93.838 – Lung Diseases Research 93.839 – Blood Diseases and Resources Research 93.840 – Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93.855 – Allergy and Infectious Diseases Research |
| Last updated on Grants.gov | Aug 12, 2025 |
| Archive date | Dec 24, 2027 |
Who can apply
Browse similar: Nonprofits · Small businesses · For-profit companies · State governments · Local governments · Tribal governments & organizations · Colleges & universities · School districts · Public housing authorities
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Native American tribal governments (federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than federally recognized tribal governments)
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others (see the eligibility details in the listing)
Additional eligibility information (excerpt from the listing):
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. …
Description
Excerpt from the official synopsis on Grants.gov (shortened; read the full text on the official listing):
This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.
Read the full listing on Grants.gov → · Agency's announcement page
More Department of Health and Human Services grants closing soon
All →- 2days leftNCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)NonprofitsSmall businessesFor-profit companies+6 moreHealth
- 2days leftNCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NonprofitsSmall businessesFor-profit companies+6 moreHealth
- 2days leftNCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)NonprofitsSmall businessesFor-profit companies+6 moreHealth
- 2days leftNIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NonprofitsSmall businessesFor-profit companies+6 moreEducation
More education grants closing soon
All →- 5days leftEthical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)NonprofitsSmall businessesFor-profit companies+6 moreEducation
- 6days leftSecondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)NonprofitsSmall businessesFor-profit companies+6 moreEducation
- 7days leftEthical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)NonprofitsSmall businessesFor-profit companies+6 moreEducation
- 7days leftEthical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)NonprofitsSmall businessesFor-profit companies+6 moreEducation